Cell Reports (Jun 2022)
Spatial region-resolved proteome map reveals mechanism of COVID-19-associated heart injury
- Ling Leng,
- Jie Ma,
- Pei-Pei Zhang,
- Si-Chi Xu,
- Xiao Li,
- Ye Jin,
- Jun Cai,
- Rui Tang,
- Lei Zhao,
- Zhi-Cheng He,
- Man-Sheng Li,
- Hui Zhang,
- Liang-Rui Zhou,
- Zhi-Hong Wu,
- Tian-Ran Li,
- Yun-Ping Zhu,
- Yu-Jie Wang,
- Hai-Bo Wu,
- Yi-Fang Ping,
- Xiao-Hong Yao,
- Chu-Hong Zhu,
- Hai-Tao Guo,
- Le-Yong Tan,
- Zhi-Yong Liang,
- Xiu-Wu Bian,
- Shu-Yang Zhang
Affiliations
- Ling Leng
- Stem Cell and Regenerative Medicine Lab, Department of Medical Science Research Center, State Key Laboratory of Complex Severe and Rare Diseases, Translational Medicine Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China; Corresponding author
- Jie Ma
- State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China
- Pei-Pei Zhang
- Department of Pathology, The First Hospital Affiliated to University of Science and Technology of China (USTC), Intelligent Pathology Institute, Division of Life Sciences and Medicine, USTC, Hefei, Anhui 230036, China; Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing 400038, China; Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
- Si-Chi Xu
- Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China
- Xiao Li
- State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China
- Ye Jin
- Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China
- Jun Cai
- Department of Pathology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
- Rui Tang
- Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing 400038, China
- Lei Zhao
- Department of Pathology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
- Zhi-Cheng He
- Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing 400038, China
- Man-Sheng Li
- State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China
- Hui Zhang
- Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China
- Liang-Rui Zhou
- Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China
- Zhi-Hong Wu
- Stem Cell and Regenerative Medicine Lab, Department of Medical Science Research Center, State Key Laboratory of Complex Severe and Rare Diseases, Translational Medicine Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China
- Tian-Ran Li
- Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing 400038, China
- Yun-Ping Zhu
- State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China; Basic Medical School, Anhui Medical University, Anhui 230032, China
- Yu-Jie Wang
- Stem Cell and Regenerative Medicine Lab, Department of Medical Science Research Center, State Key Laboratory of Complex Severe and Rare Diseases, Translational Medicine Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China
- Hai-Bo Wu
- Department of Pathology, The First Hospital Affiliated to University of Science and Technology of China (USTC), Intelligent Pathology Institute, Division of Life Sciences and Medicine, USTC, Hefei, Anhui 230036, China
- Yi-Fang Ping
- Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing 400038, China
- Xiao-Hong Yao
- Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing 400038, China
- Chu-Hong Zhu
- Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
- Hai-Tao Guo
- Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing 400038, China
- Le-Yong Tan
- Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing 400038, China
- Zhi-Yong Liang
- Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China; Corresponding author
- Xiu-Wu Bian
- Department of Pathology, The First Hospital Affiliated to University of Science and Technology of China (USTC), Intelligent Pathology Institute, Division of Life Sciences and Medicine, USTC, Hefei, Anhui 230036, China; Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing 400038, China; Corresponding author
- Shu-Yang Zhang
- Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China; Tsinghua-Peking Center for Life Sciences, Tsinghua University, Beijing 100084, China; Corresponding author
- Journal volume & issue
-
Vol. 39,
no. 11
p. 110955
Abstract
Summary: Direct myocardial and vascular injuries due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-driven inflammation is the leading cause of acute cardiac injury associated with coronavirus disease 2019 (COVID-19). However, in-depth knowledge of the injury characteristics of the heart affected by inflammation is lacking. In this study, using a quantitative spatial proteomics strategy that combines comparative anatomy, laser-capture microdissection, and histological examination, we establish a region-resolved proteome map of the myocardia and microvessels with obvious inflammatory cells from hearts of patients with COVID-19. A series of molecular dysfunctions of myocardia and microvessels is observed in different cardiac regions. The myocardia and microvessels of the left atrial are the most susceptible to virus infection and inflammatory storm, suggesting more attention should be paid to the lesion and treatment of these two parts. These results can guide in improving clinical treatments for cardiovascular diseases associated with COVID-19.
